文献速递胸部肿瘤

非小细胞肺癌高肿瘤突变负荷与免疫浸润增加及PD-L1阻断跨PD-L1表达水平临床结局改善的关联

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
PubMed 文献 · JAMA Oncol · 2022-01-01

这项多中心队列研究纳入1552例接受PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者,评估肿瘤突变负荷(TMB)与疗效的关系。回归树模型确定TMB分组为低TMB(≤19.0突变/兆碱基)和高TMB(>19.0突变/兆碱基),高TMB与客观缓解率、无进展生存和总生存的改善相关,且在PD-L1表达各亚组中均一致。

要点

  • 高TMB(>19.0突变/兆碱基)与PD-1/PD-L1抑制剂治疗的客观缓解率、无进展生存和总生存改善相关。
  • 高TMB且PD-L1表达≥50%的患者客观缓解率高达57%,低TMB且PD-L1表达<1%的患者客观缓解率低至8.7%。
  • 高TMB与CD8阳性、PD-L1阳性T细胞浸润增加及先天和适应性免疫应答特征上调相关。

核心结论

  • TMB水平升高与免疫细胞浸润及炎症性T细胞介导的应答相关,导致非小细胞肺癌各PD-L1表达亚组对PD-1/PD-L1阻断的敏感性增加。

研究设计与样本

  • 多中心队列研究,纳入在Dana-Farber癌症研究所、纪念斯隆凯特琳癌症中心和Stand Up To Cancer/Mark Foundation数据集中接受PD-1/PD-L1抑制剂治疗的晚期非小细胞肺癌患者。
  • 共纳入1552例患者,中位(范围)年龄66(22-92)岁,830例(53.5%)为女性,1347例(86.8%)为非鳞状组织学类型。
  • 收集患者2013年9月至2020年9月间的临床病理和基因组数据,数据分析于2021年11月至2022年2月进行。

主要发现

  • 回归树模型确定TMB分组为低TMB(≤19.0突变/兆碱基)和高TMB(>19.0突变/兆碱基),在发现队列(MSKCC)和两个独立队列(DFCI和SU2C/Mark Foundation)中均与客观缓解率、无进展生存和总生存的改善相关。
  • 在PD-L1肿瘤比例评分<1%、1%至49%和≥50%的各亚组中,TMB水平均与免疫治疗结局的显著改善相关。
  • 高TMB且PD-L1表达≥50%的患者客观缓解率高达57%,低TMB且PD-L1表达<1%的患者客观缓解率低至8.7%。
  • 多重免疫荧光和转录组分析显示,高TMB水平与CD8阳性、PD-L1阳性T细胞浸润增加、肿瘤和免疫细胞上PD-L1表达增加以及先天和适应性免疫应答特征上调相关。

关键数值与推荐

  • TMB分组阈值:低TMB(≤19.0突变/兆碱基)和高TMB(>19.0突变/兆碱基)。
  • 高TMB且PD-L1表达≥50%的患者客观缓解率为57%。
  • 低TMB且PD-L1表达<1%的患者客观缓解率为8.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about the optimal TMB threshold that best discriminates improved outcomes of immune checkpoint inhibitor therapy among patients with non-small cell lung cancer (NSCLC). OBJECTIVES: To determine the association between increasing TMB levels and immunotherapy efficacy across clinically relevant programmed death ligand-1 (PD-L1) levels in patients with NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included patients with advanced NSCLC treated with immunotherapy who received programmed cell death-1 (PD-1) or PD-L1 inhibition in the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center (MSKCC), and in the Stand Up To Cancer (SU2C)/Mark Foundation data sets. Clinicopathological and genomic data were collected from patients between September 2013 and September 2020. Data analysis was performed from November 2021 to February 2022. EXPOSURES: Treatment with PD-1/PD-L1 inhibition without chemotherapy. MAIN OUTCOMES AND MEASURES: Association of TMB levels with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: In the entire cohort of 1552 patients with advanced NSCLC who received PD-1/PD-L1 blockade, the median (range) age was 66 (22-92) years, 830 (53.5%) were women, and 1347 (86.8%) had cancer with nonsquamous histologic profile. A regression tree modeling ORR as a function of TMB identified 2 TMB groupings in the discovery cohort (MSKCC), defined as low TMB (≤19.0 mutations per megabase) and high TMB (>19.0 mutations per megabase), which were associated with increasing improvements in ORR, PFS, and OS in the discovery cohort and in 2 independent cohorts (DFCI and SU2C/Mark Foundation). These TMB levels also were associated with significant improvements in outcomes of immunotherapy in each PD-L1 tumor proportion score subgroup of less than 1%, 1% to 49%, and 50% or higher. The ORR to PD-1/PD-L1 inhibition was as high as 57% in patients with high TMB and PD-L1 expression 50% or higher and as low as 8.7% in patients with low TMB and PD-L1 expression less than 1%. Multiplexed immunofluorescence and transcriptomic profiling revealed that high TMB levels were associated with increased CD8-positive, PD-L1-positive T-cell infiltration, increased PD-L1 expression on tumor and immune cells, and upregulation of innate and adaptive immune response signatures. CONCLUSIONS AND RELEVANCE: These findings suggest that increasing TMB levels are associated with immune cell infiltration and an inflammatory T-cell-mediated response, resulting in increased sensitivity to PD-1/PD-L1 blockade in NSCLC across PD-L1 expression subgroups.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ricciuti B, Wang X, Alessi JV, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol. 2022. PMID: 35708671. doi:10.1001/jamaoncol.2022.1981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。